| Aggregate Evidence Quality . | Grade C . |
|---|---|
| Benefits | Early detection and treatment of HTN in children with T1DM and T2DM may reduce future CV and kidney disease |
| Risks, harm, cost | Risk of drug adverse effects and polypharmacy |
| Benefit–harm assessment | Preponderance of benefit |
| Intentional vagueness | None |
| Role of patient preferences | Family concerns about additional testing and/or medication may need to be addressed |
| Exclusions | None |
| Strength | Weak to moderate recommendation |
| Key references | 14,110,111,494 |
| Aggregate Evidence Quality . | Grade C . |
|---|---|
| Benefits | Early detection and treatment of HTN in children with T1DM and T2DM may reduce future CV and kidney disease |
| Risks, harm, cost | Risk of drug adverse effects and polypharmacy |
| Benefit–harm assessment | Preponderance of benefit |
| Intentional vagueness | None |
| Role of patient preferences | Family concerns about additional testing and/or medication may need to be addressed |
| Exclusions | None |
| Strength | Weak to moderate recommendation |
| Key references | 14,110,111,494 |